Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Acute Treatment with Rimegepant 75 mg Confers Clinically Relevant Improvement in Lost Time (Days) Due to Migraine: Results From a 1-Year, Open-Label Safety Study (BHV3000-201)
Headache
Headache Posters (7:00 AM-5:00 PM)
017

Migraine is among the most disabling neurologic conditions globally, with the burden falling most heavily on adults in their most productive years (age 18-55). Rimegepant, a CGRP small molecule receptor blocker, is approved as an acute treatment for migraine.

To describe long term improvements in time lost due to migraine associated with acute treatment with Rimegepant 75 mg.

The study population was derived from a multicenter, long-term (1 year), open-label safety study of rimegepant 75 mg oral tablet (NCT03266588). Eligible subjects included adults with ≥1 year history of migraine (ICHD-3 beta) who treated migraine attacks of any pain intensity with rimegepant 75 mg up to once daily as-needed (PRN) for up to 52 weeks. Two enrollment groups were defined based on historic migraine frequency (i.e. 2-8PRN, 9-14PRN). Lost time (days) due to migraine (LTM) was assessed using total Migraine Disability Assessment Scale (MIDAS) score administered per 3 months at baseline,12, 24,36, and 52 weeks of follow up. Paired t-tests were conducted to determine significant differences at 52 weeks.

Among 1,585 patients, mean (SE),LTM at baseline,12, 24, 36,and 52 weeks were 28.2 (0.81),18.5 (0.72),16.8 (0.79),16.5 (0.97),and 16.1(0.95) days respectively for the 2-8PRN enrollment group (p<.0001), and 46.6 (1.87), 27.1 (1.81), 23.3 (1.75),21.1 (1.77),and 20.9 (1.99) days respectively for the 9-14PRN group (p<.0001). Mean % changes (95% CI) in LTM were -35% (-43%, -26%), -42% (-51%,-32%),-41% (-54%,-29%),and -43% (-56%,-30%) for the 2-8PRN group and -38% (-48%,-28%),-43% (-53%,-33%),-47% (-60%,-33%),and -47% (-57%,-37%) for the 9-14PRN group. Combined group (with baseline MMD ≥ 5; N = 1,114) % changes were -36% (-42%,-30%),-42% (-48%,-36%),-43% (-50%,-37%), and -45% (-51%,-40%).

Repeated long term treatment of acute migraine with rimegepant 75 mg was associated with clinically relevant improvements in days lost due to migraine. These improvements would likely contribute to better patient productivity due to reduced migraine-related disability.

Authors/Disclosures
Gilbert J. L'Italien
PRESENTER
Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
Evan Popoff Evan Popoff has nothing to disclose.
Diego Fernandez-Vial (University of Kentucky) Linda Harris has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Linda Harris has received stock or an ownership interest from Biohaven Pharmaceuticals.
Karissa Johnston Karissa Johnston has nothing to disclose.
Robert Croop, MD Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has received personal compensation for serving as an employee of Pfizer Inc.. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has stock in Biohaven Ltd.. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
Vladimir Coric Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.